Read More

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes With CTLA-4 Protein To Selectively Target Immune Cells With Potential To Deliver Targeted Therapies Across Multiple Diseases

Using proprietary exosome tethering modification technology, Treg derived exosomes were engineered with a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) to increase selective targeting to immune

COYA

Read More

BiomX to Present Data From Ongoing Phase 1b/2a Study Evaluating BX004 For The Treatment Of Chronic Pseudomonas aeruginosa Pulmonary Infections In Patients With Cystic Fibrosis At The European Respiratory Society International Congress 2023

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the

PHGE